News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Orion to receive an upfront payment of USD 290 million
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Shares and American Depositary Shares of Olink for $26.00 per Share
Comprehensive clinical development programs being initiated for each investigational candidate
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
The product is expected to start contributing meaningfully to the revenue from FY25
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Subscribe To Our Newsletter & Stay Updated
